Related Experiment Video

Updated: Jul 19, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Increased levels of lipoprotein (a) in Crohn's disease: a relation to thrombosis?

I E Koutroubakis1, N Malliaraki, E Vardas

  • 1Department of Gastroenterology, University Hospital Heraklion, Crete, Greece. ktjohn@her.forthnet.gr

European Journal of Gastroenterology & Hepatology
|December 14, 2001
PubMed

Insights

Patients with Crohn's disease show elevated lipoprotein (a) levels, a known risk factor for thrombosis. These findings suggest a potential link between altered lipoprotein profiles and increased thrombotic risk in Crohn's disease patients.

Area of Science:

  • Cardiovascular Medicine
  • Gastroenterology
  • Clinical Biochemistry

Background:

  • Lipoprotein (a) is a risk factor for thrombosis due to structural similarities with plasminogen.
  • Inflammatory bowel disease (IBD) patients have a higher incidence of thromboembolic events.

Purpose of the Study:

  • To investigate the role of lipoprotein (a) and associated lipids/apolipoproteins in Greek patients with ulcerative colitis (UC) and Crohn's disease (CD).

Main Methods:

  • Serum levels of lipoprotein (a), total cholesterol, HDL, LDL, triglycerides, apolipoprotein A-1, and apolipoprotein B-100 were measured.
  • The study included 129 IBD patients (66 UC, 63 CD) and 66 healthy controls.

Main Results:

  • Crohn's disease patients exhibited significantly higher mean lipoprotein (a) levels (41.2 mg/dl) compared to controls (22.9 mg/dl).
  • CD patients showed lower mean apolipoprotein A-1 and B-100 levels. UC patients had lower apolipoprotein B-100 levels.
  • Elevated lipoprotein (a) (>30 mg/dl) was observed in 46% of CD patients, 23% of UC patients, and 17% of controls.

Conclusions:

  • Crohn's disease patients display distinct lipoprotein (a) and apolipoprotein patterns compared to UC patients and healthy individuals.
  • These alterations in CD may contribute to an increased risk of thrombosis.
Abstract

More Related Videos

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

The Isolation of Flowing Mesenteric Lymph in Mice to Quantify In Vivo Kinetics of Dietary Lipid Absorption and Chylomicron Secretion06:14

The Isolation of Flowing Mesenteric Lymph in Mice to Quantify In Vivo Kinetics of Dietary Lipid Absorption and Chylomicron Secretion

Published on: November 30, 2022

Related Concept Videos

Inflammation01:38

Inflammation

Overview
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...